Navigation Links
Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
Date:6/11/2009

SAN FRANCISCO, June 11 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Canada), a clinical-stage biopharmaceutical company, announced today that a $10 million grant from the Ontario Institute for Cancer Research (OICR) has been received by the Centre for Cancer Therapeutics at Ottawa Hospital Research Institute (OHRI). A large portion of this grant will fund research and development in the lab of Dr. John Bell, Jennerex's chief collaborator for the discovery and development of oncolytic viral therapeutics for cancer patients. Funding will support the translation of discoveries into medical products with the potential to prolong the lives of cancer patients. The grant, which provides $10 million (CAD) over four years, will fund the research and development of novel therapeutics including the development of Jennerex's oncolytic viral therapy products. Jennerex products have shown tumor destruction and safety in Phase 1 and 2 clinical trials.

"We are very pleased that Dr. Bell and Jennerex's oncolytic virus technologies have been given this vote of confidence by the Ontario Institute for Cancer Research. This funding will bolster the translation of Dr. Bell's promising research into important cancer therapeutics," stated David H. Kirn, M.D., president and chief executive officer of Jennerex. "We believe that there is significant potential in Ontario for medical innovation and development, and we value our partnerships in Ontario a great deal."

"This collaboration has been a great example of academia and industry working together to translate biological research into cutting edge therapies quickly and effectively," said Dr. John Bell, Senior Scientist at the Ottawa Hospital Research Institute and Professor of Medicine at the University of Ottawa.

Jennerex is conducting Phase 2 clinical trials for several types of cancer in Ontario, Canada. In addition, the company has a strong and co
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
2. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
3. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
4. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
5. Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
11. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Inc. (NYSE: RMD ) today announced results for ... 30, 2014.  Revenue for the quarter was $415.2 million, flat ... percent decrease on a constant currency basis). Net income was ... quarter ended June 30, 2013. Diluted earnings per share for ... to the quarter ended June 30, 2013.  ...
(Date:7/31/2014)... (NASDAQ: CPHD ) today announced that its executives ... to participate via webcast. Wedbush Life ... Wednesday, August 13, 2014 at 9.10 a.m. Eastern Time ... York, NY Thursday, September 4, 2014 at 8.30 ... access the live webcasts for these events, please visit Cepheid,s ...
(Date:7/31/2014)... 31, 2014  UBM Medica US announces that ... for oncologists, presents exclusive slide shows dealing with communication ... quality cancer care. Cancer Network, ... offers news, blogs, and podcasts about the latest clinical ... care: , End-of-life care is challenging for ...
Breaking Medicine Technology:RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13Cepheid to Webcast Upcoming Financial Presentations 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 3
... , NEW YORK, Dec. 7 ... updated efficacy and safety data as well as new ... in combination with bortezomib (Velcade(R)) (+/- dexamethasone) in patients ... "A Multicenter Phase 1/2 Study Evaluating the Safety and ...
... , ENGLEWOOD, Colo., Dec. 7 ... system, DoseEdge(TM), during this week,s ASHP Midyear Clinical Meeting ... patient safety and pharmacy efficiency through the management of ... easily into current pharmacy practice and techniques, while providing ...
Cached Medicine Technology:Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 2Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 3
(Date:8/1/2014)... York, New York (PRWEB) August 01, 2014 ... http://www.gynecaremorcellatorlawsuit.com/ ) on behalf of women who allegedly experienced ... of power morcellators in gynecological surgeries, Bernstein Liebhard LLP ... to withdraw a number of power morcellators marketed by ... a report from The New York Times, some critics ...
(Date:8/1/2014)... benefits of a cancer diagnosis may improve health outcomes ... conducted by a researcher at the University of Houston ... writing intervention is the writing instruction. Otherwise, writing is ... a journal can be therapeutic, but oftentimes we don,t ... or not," said Qian Lu, assistant professor and director ...
(Date:8/1/2014)... August 01, 2014 On Monday, June ... NextGen User Symposium in San Francisco, CA. Now in ... the JW Marriott Union Square hotel. , “We are ... up to speed with ACA compliance issues,” Quirk Healthcare ... The symposium provides attendees guidance with NextGen implementation and ...
(Date:8/1/2014)... August 01, 2014 According to ... by Geography (Asia-Pacific, North America, Europe, & ROW), ... by Fuel Type (Gasoline & Diesel), by After-Treatment ... - Trends & Forecasts to 2019", defines and ... an analysis of major countries in all the ...
(Date:8/1/2014)... Scientists at Albert Einstein College of Medicine ... aid in digestion help keep the intestinal lining intact. ... , could yield new therapies for inflammatory bowel disease ... The research involved the intestinal microbiome, which contains some ... promoting or preventing disease is a major emerging field ...
Breaking Medicine News(10 mins):Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 4Health News:Expressive writing may help breast cancer survivors 2Health News:Expressive writing may help breast cancer survivors 3Health News:Quirk Healthcare Foundation Hosts Fifth Annual California NextGen User Symposium and Launches First Annual Florida NextGen User Symposium 2Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 2Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 3Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 4Health News:'Normal' bacteria vital for keeping intestinal lining intact 2
... scientists implicates a new protein in obesity development and highlights ... resistance. Jorge Moscat, PhD, chair of UC,s ... ERK are involved in adipogeneis, (the development of adipocytes, or ... works together. The study is published online in ...
... , BOULDER, Colo. , ... of Functional Fitness on Walk the Talk ... Sam Iannetta , a champion powerlifter, tells—and shows—how ... healing injuries, whatever your fitness practice: yoga, cycling, ...
... SHANGHAI , Feb. 12 General Nutrition ... announced today that it, together with its parent company, has entered ... Bright Food (Group) Co., LTD (Bright Food). The partnership, to be ... market. Bright Food , a leading state-owned conglomerate in ...
... received male donors, plasma had worse outcomes, study found ... blood-banking industry discourages transfusing the blood product known as ... reaction in the recipients. , But now researchers have ... have advantages. , Plasma is the fluid in ...
... Touching down toe-first is less economical in humans, research shows , ... to walk heel-first than to walk on the balls of your ... Compared with heel-first walking, it takes 83 percent more energy to ... on the balls of your feet, according to the University of ...
... ... has just released their emWave® Desktop product. emWave Desktop works on both PC and ... ... has just released their emWave® Desktop product. emWave Desktop works on both PC and ...
Cached Medicine News:Health News:Research highlights role of protein pair in obesity regulation 2Health News:GNC Announces Entry to China's Nutritional Products in Partnership with Bright Food 2Health News:GNC Announces Entry to China's Nutritional Products in Partnership with Bright Food 3Health News:GNC Announces Entry to China's Nutritional Products in Partnership with Bright Food 4Health News:Restrictions on Plasma From Female Donors May Need Revisiting 2Health News:Heel-First Walking Conserves Energy 2Health News:HeartMath Announces the Release of Their New emWave Desktop Software 2Health News:HeartMath Announces the Release of Their New emWave Desktop Software 3Health News:HeartMath Announces the Release of Their New emWave Desktop Software 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: